Medtech company to market novel diagnostic test in US
The Food and Drug Administration has approved a novel diagnostic test from a Danish medtech company for marketing in the US.
by Leonora Beck
American breast cancer patients will now be given the opportunity to utilize a new diagnostic test from the Danish medtech company, Dako. The company, which was bought by Agilent in 2012, has won approval of the test, Clone EP1, from US health authorities, FDA, the Danes reveal in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Dako-CEO: Important and fast-growing business area
For abonnenter
Danish medtech company collaborating with drug giants
For abonnenter
